Sunshine Biopharma director Andrew Keller to leave board at next annual meeting
Dr. Andrew Keller informed Sunshine Biopharma on August 25, 2026 that he does not plan to stand for another term on its board.
Sunshine Biopharma Inc. disclosed in an 8-K filing that Dr. Andrew Keller, a director of the company, informed the company on August 25, 2026 that he does not intend to seek or accept reelection to the board of directors when his current term ends.1
Keller's present term is set to run through the company's next annual shareholder meeting.1 The filing did not state a reason for the decision.
The 8-K was signed on behalf of the company by CEO Dr. Steve N. Slilaty, with the filing dated August 28, 2026. Sunshine Biopharma, incorporated in Colorado, trades on Nasdaq under the ticker SBFM, with its warrants trading under SBFMW.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.